Upfront triple therapy with parenteral prostanoid as a bridge to balloon pulmonary angioplasty in severe chronic thromboembolic pulmonary hypertension.

Nicolas PilieroMuriel SalvatMathieu FinasFlorence CuriozJulie TracletKaïs AhmadLaurent BertolettiEstelle VautrinHélène BouvaistBruno Degano

Published in: ERJ open research (2024)

In patients with very severe CTEPH eligible for BPA, it is possible to achieve major haemodynamic improvement with upfront triple PH therapy including epoprostenol and then to perform angioplasties https://bit.ly/3vZZvib.

Keyphrases

pulmonary hypertension
early onset
pulmonary arterial hypertension
atrial fibrillation
stem cells
cell therapy
replacement therapy
smoking cessation